Devyser Diagnostics (DVYSR) Stock Overview
Engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for DVYSR from our risk checks.
DVYSR Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Devyser Diagnostics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 90.20 |
| 52 Week High | SEK 159.60 |
| 52 Week Low | SEK 83.30 |
| Beta | 0.68 |
| 1 Month Change | -13.60% |
| 3 Month Change | -20.46% |
| 1 Year Change | -28.41% |
| 3 Year Change | 14.47% |
| 5 Year Change | n/a |
| Change since IPO | 1.35% |
Recent News & Updates
Earnings Update: Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
Feb 15
Earnings Miss: Devyser Diagnostics AB (publ) Missed EPS And Analysts Are Revising Their Forecasts
Nov 08Recent updates
Earnings Update: Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
Feb 15Earnings Miss: Devyser Diagnostics AB (publ) Missed EPS And Analysts Are Revising Their Forecasts
Nov 08Are Investors Undervaluing Devyser Diagnostics AB (publ) (STO:DVYSR) By 21%?
Nov 04Devyser Diagnostics AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jul 25Revenues Tell The Story For Devyser Diagnostics AB (publ) (STO:DVYSR) As Its Stock Soars 31%
Jul 23Optimistic Investors Push Devyser Diagnostics AB (publ) (STO:DVYSR) Shares Up 27% But Growth Is Lacking
May 10Devyser Diagnostics AB (publ) (STO:DVYSR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 02Companies Like Devyser Diagnostics (STO:DVYSR) Are In A Position To Invest In Growth
Apr 09Devyser Diagnostics AB (publ) (STO:DVYSR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Feb 17Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts
Jun 14Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company
Mar 20Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates
Feb 23Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business
Feb 22Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company
Dec 09These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts
Aug 30Devyser Diagnostics AB (publ) (STO:DVYSR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 14Shareholder Returns
| DVYSR | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -5.5% | -2.4% | 1.1% |
| 1Y | -28.4% | 2.4% | 7.1% |
Return vs Industry: DVYSR underperformed the Swedish Biotechs industry which returned 3.2% over the past year.
Return vs Market: DVYSR underperformed the Swedish Market which returned 2.1% over the past year.
Price Volatility
| DVYSR volatility | |
|---|---|
| DVYSR Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: DVYSR has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: DVYSR's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 116 | Jan Wahlstrom | devyser.com |
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up.
Devyser Diagnostics AB (publ) Fundamentals Summary
| DVYSR fundamental statistics | |
|---|---|
| Market cap | SEK 1.50b |
| Earnings (TTM) | -SEK 8.40m |
| Revenue (TTM) | SEK 250.50m |
Is DVYSR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DVYSR income statement (TTM) | |
|---|---|
| Revenue | SEK 250.50m |
| Cost of Revenue | SEK 48.60m |
| Gross Profit | SEK 201.90m |
| Other Expenses | SEK 210.30m |
| Earnings | -SEK 8.40m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Mar 25, 2026
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 80.60% |
| Net Profit Margin | -3.35% |
| Debt/Equity Ratio | 0.08% |
How did DVYSR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/27 18:07 |
| End of Day Share Price | 2026/02/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Devyser Diagnostics AB (publ) is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Erik Hultgård | DNB Carnegie |
| Ludvig Lundgren | Nordea Markets |